Predictors of first recurrence of Clostridium difficile infection: implications for initial management
about
Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infectionsWSES guidelines for management of Clostridium difficile infection in surgical patientsRisk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic reviewRisk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study.Clostridium difficile infection in older adultsHealthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, TexasThe role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: a case-control study.Serum mannose-binding lectin concentration, but not genotype, is associated with Clostridium difficile infection recurrence: a prospective cohort study.Procalcitonin levels associate with severity of Clostridium difficile infectionA prediction model for Clostridium difficile recurrenceClostridium difficile in the Long-Term Care Facility: Prevention and ManagementEpidemiology of Clostridium difficile infection among active duty United States military personnel (1998-2010).Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiariesRecurrent Clostridium difficile infection and the microbiome.Predictors and outcomes of readmission for Clostridium difficile in a national sample of medicare beneficiariesRecurrent Clostridium difficile infection: From colonization to cure.Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach.Asymptomatic and yet C. difficile-toxin positive? Prevalence and risk factors of carriers of toxigenic Clostridium difficile among geriatric in-patients.Economic burden of Clostridium difficile in five hospitals of the Florence health care system in ItalyFidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian OutcomesA cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in GermanyElevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infectionFidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.Therapy of Clostridium difficile infection: perspectives on a changing paradigm.Vaccines against Clostridium difficile.Clostridium difficile infection in the postcolectomy patient.Clostridium difficile infection in patients with liver disease: a review.Prediction of Recurrent Clostridium Difficile Infection Using Comprehensive Electronic Medical Records in an Integrated Healthcare Delivery System.Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection.Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.Post-hospitalization Treatment Regimen and Readmission for C. difficile Colitis in Medicare Beneficiaries.Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.The Attributable Burden of Clostridium difficile Infection to Long-Term Care Facilities Stay: A Clinical Study.Risk factors and impact of Clostridium difficile recurrence on haematology patients.Recurrent Clostridium difficile Infection in Children: Patient Risk Factors and Markers of Intestinal Inflammation.The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort.
P2860
Q26752760-33B7A173-75F5-48E1-B682-729724FA010AQ26795429-98F4DAE8-EF67-41BD-B646-D1A83DB9BD36Q27021390-129AD0A3-0016-4281-AF88-EDD2A2B4E8EAQ33729925-FCEB8126-72CD-42C9-B90C-696101BA83BDQ33771594-E20354FF-56C2-483B-AE35-CD37B0335669Q33945833-078D898B-297B-4A5F-82FE-17E9B74DFC8FQ34074371-5A60D0F3-608A-469B-A4BB-0185173E7798Q34393517-E288B6A5-55D8-44CF-BD49-D12CD7B5601FQ34625689-CEB71FCA-5962-4C5B-996E-1DD4CBACC7F3Q35054817-CFE98B87-8929-46AC-90BF-2951C9A13D47Q35065783-8B2538F8-42C4-4659-9F1C-ECC2B4C8CFBAQ35076928-17AF6CFF-42E4-4F32-BAAA-DCB803869828Q35546417-46C24D91-9F29-4496-98F9-89FA3FEEEEE7Q35685694-892FE7CC-84D3-422D-BB38-CC3AC26A4C7EQ35711361-728DDECC-EF7F-4445-8E3A-1A02246551B4Q35822541-B33CBF5A-9B7F-461F-B421-3DEF914DDBEDQ35930922-DE9CEC00-89DE-4C6A-851D-B33BFE20FC03Q36055810-7F6A3A69-8853-4B4A-8E89-D97692D6FF12Q36193300-5B441B42-C08F-437B-858E-F26B49957350Q36307202-3293AC49-3C88-4DBF-96D0-F2BB3D688F4CQ36996876-F8A20900-5DBF-489D-BD41-5A01F4E44C70Q37297999-C9235C0E-3A69-447D-BDBC-7C11852B7E4BQ37302441-FD9AD394-753B-4934-8093-8081107D7192Q37588248-9D942836-D762-4F38-84F3-63730471B94EQ37696597-4EF22891-4490-4296-A1FB-5576A9C3B836Q38139991-B9D318DB-1BB7-4690-98CC-EBB2CCC67B15Q38196682-E8F8775A-C2C1-4864-AB11-6A61B30551F5Q38268703-EB8E15C5-BC43-46E4-BAEB-B0C3C2343218Q38600142-7A6A9DB9-45AC-48F3-A807-AA91D9BC4240Q38611301-845752AB-2FC9-40FE-9FAD-459316EACA58Q38716945-09F4BB90-6E77-48AB-8B84-66949EEC1285Q38904050-1E42DC9B-5EDB-468D-BBB2-DC9563B92FB0Q39175350-544C96A8-7680-4C32-9DB7-2283D70F4CA7Q39640585-5DCC33C7-BA3D-4EEB-9661-B823A3FCBFD0Q40119535-D72025A6-4629-4108-8FE5-8F18D5851003Q40130108-FE6660B2-08BB-4F9C-A5E2-E5110E5C5258Q40287685-981C647A-4C41-4946-9944-67C7A2291328Q40337382-2D576228-B85E-4263-9CC4-4CFCF9074637Q40408914-E54EC9FE-4A79-4078-B8BE-D09FC4B3619DQ40513250-4272E2F6-D7DF-4683-AE7A-D6046B45070B
P2860
Predictors of first recurrence of Clostridium difficile infection: implications for initial management
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Predictors of first recurrence ...... cations for initial management
@ast
Predictors of first recurrence ...... cations for initial management
@en
Predictors of first recurrence ...... cations for initial management
@en-gb
type
label
Predictors of first recurrence ...... cations for initial management
@ast
Predictors of first recurrence ...... cations for initial management
@en
Predictors of first recurrence ...... cations for initial management
@en-gb
prefLabel
Predictors of first recurrence ...... cations for initial management
@ast
Predictors of first recurrence ...... cations for initial management
@en
Predictors of first recurrence ...... cations for initial management
@en-gb
P2093
P2860
P50
P356
P1154
2-s2.0-84863651274
P1476
Predictors of first recurrence ...... cations for initial management
@en
P2093
A Sarah Walker
Alison Vaughan
David Griffiths
David Wyllie
Derrick W Crook
Infections in Oxfordshire Research Database
John Finney
Lily O'Connor
Timothy E A Peto
P2860
P304
P356
10.1093/CID/CIS356
P407
P478
55 Suppl 2
P577
2012-08-01T00:00:00Z